NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

$14.91
+0.23 (+1.57%)
(As of 11:01 AM ET)
Today's Range
$14.57
$15.04
50-Day Range
$14.59
$20.18
52-Week Range
$12.95
$25.47
Volume
26,401 shs
Average Volume
803,260 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.25

Arcus Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
175.0% Upside
$41.25 Price Target
Short Interest
Bearish
17.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Arcus Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$320 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.01 out of 5 stars

Medical Sector

564th out of 910 stocks

Pharmaceutical Preparations Industry

257th out of 426 stocks

RCUS stock logo

About Arcus Biosciences Stock (NYSE:RCUS)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Stock Price History

RCUS Stock News Headlines

Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
Navigating 5 Analyst Ratings For Arcus Biosciences
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/23/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
577
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.25
High Stock Price Target
$70.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+180.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-307,000,000.00
Net Margins
-262.39%
Pretax Margin
-257.27%

Debt

Sales & Book Value

Annual Sales
$117 million
Book Value
$6.17 per share

Miscellaneous

Free Float
78,326,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
0.81
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Terry J. Rosen Ph.D. (Age 64)
    Co-Founder, Chairman & CEO
    Comp: $756.11k
  • Dr. Juan Carlos Jaen Ph.D. (Age 66)
    Co- Founder & President
    Comp: $931.14k
  • Mr. Robert C. Goeltz IIMr. Robert C. Goeltz II (Age 51)
    Principal Financial Officer & CFO
    Comp: $745.29k
  • Ms. Jennifer A. Jarrett M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $925.29k
  • Dr. Dimitry S.A. Nuyten M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700.34k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Alexander Azoy (Age 48)
    VP of Finance & Principal Accounting Officer
  • Dr. Jonathan Yingling Ph.D. (Age 55)
    Chief Scientific Officer

RCUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price target for 2024?

8 Wall Street analysts have issued 1 year target prices for Arcus Biosciences' stock. Their RCUS share price targets range from $23.00 to $70.00. On average, they anticipate the company's stock price to reach $41.25 in the next year. This suggests a possible upside of 175.0% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2024?

Arcus Biosciences' stock was trading at $19.10 on January 1st, 2024. Since then, RCUS shares have decreased by 21.5% and is now trading at $15.00.
View the best growth stocks for 2024 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) issued its quarterly earnings results on Wednesday, February, 21st. The company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.01. The firm had revenue of $31 million for the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 57.17% and a negative net margin of 262.39%. Arcus Biosciences's revenue for the quarter was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.93) earnings per share.

What ETFs hold Arcus Biosciences' stock?
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%), Diversified Trust Co (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RCUS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners